AbbVie Inc. (ABBV) has recently drawn notable attention from investors and analysts. The bio-pharmaceutical company has been downgraded to Peer Perform from Outperform by Wolfe Research. However, the company has also been given a Buy rating by Berenberg Bank and HSBC has upgraded its position on AbbVie, raising the price target to $265. The company is also reportedly near completion of negotiations for the acquisition of Revolution Medicines, contradicting previous denials of such talks. Simultaneously, AbbVie has warned about a $1.3 billion IPR&D charge expected to impact the Q4 earnings. Apart from the chatter around acquisitions and earnings pressure, analysts are displaying a keen interest in AbbVie’s clinical developments, highlighting the ABBV-243 Phase 1 trial and the restructured OSE Immunology partnership. The company had a strong year in the market, raising questions about its valuation amid significant share price gains, with concerns about possible margin compression making some investors cautious. AbbVie expects to reveal 2025 results in early February.
Abbvie ABBV News Analytics from Tue, 26 Aug 2025 07:00:00 GMT to Sat, 10 Jan 2026 19:57:17 GMT - Rating 4 - Innovation 0 - Information 7 - Rumor -3
